An American woman has shared an account online claiming that a medicine she bought through an Indian manufacturer cost far less than the same item is priced in the United States. According to reports, she says a drug listed at about $1,000 in the US was obtained for about $25 after sourcing it from India. Her comparison—$1,000 versus $25—has prompted public debate, including criticism of the US healthcare system and claims that it operates like a “scam.”
Both outlets describe the same basic narrative: the woman highlights the large price gap between a US price point and a lower cost she paid when using an Indian supplier. However, the available reports focus mainly on her personal account and the resulting online discussion, without providing additional verification details such as the specific medication, identical formulations, distribution channels, or whether the US and India prices reflect the same dosage, brand, or regulatory pathway. The story therefore centers on the claim and the public reaction rather than an independently documented price comparison.
